The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Potent pre-clinical and early phase activity of inobrodib in multiple myeloma
Tim Somervaille, PhD, FRCP, FRCPath, The University of Manchester, UK, discusses the pre-clinical and early phase clinical activity of inobrodib, a novel bromodomain inhibitor, for the treatment of multiple myeloma. Pre-clinical studies have demonstrated promising activity, and Dr Somervaille highlights an ongoing early Phase I/IIa trial (NCT04068597) exploring this agent in patients with various hematological malignancies. Inobrodib is also being evaluated in combination with pomalidomide, which has demonstrated promising efficacy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy; Novartis: Consultancy; Bristol Myers Squibb: Consultancy; Imago Biosciences: Research Funding; Oryzon Genomics: Consultancy; CellCentric Ltd: Research Funding.
